A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Next Previous
Trial Profile

A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 11 Mar 2018

At a glance

  • Drugs Tesevatinib (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors Kadmon Corporation

    • Most Recent Events

    • 28 Aug 2017 Status changed from active, no longer recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 29 Nov 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top